This abstract is assigned to sessions
| Presentation preference | Oral presentation |
| Title | OUTCOMES OF ADALIMUMAB THERAPY IN REFRACTORY PUNCTATE INNER CHOROIDOPATHY AND MULTIFOCAL CHOROIDITIS |
| Purpose | To evaluate the outcomes of Adalimumab (ADA) in patients with refractory punctate inner choroidopathy (PIC) and multifocal choroiditis (MFC). |
| Methods | Retrospective review of medical files of patients with refractory PIC/MFC.
Demographic data and clinical characteristics, including LogMAR best-corrected visual acuity (BCVA) were collected. In addition, we recorded the dose of prednisone and types and doses of immunomodulatory therapy (IMT), the number of anti-vascular endothelial growth factor (VEGF) injections for eyes with choroidal neovascularization (CNV), and drug-associated adverse events before and after baseline. The baseline was defined at ADA initiation.
|
| Results | Ten eyes from 7 patients were included (5 with PIC, 2 with MFC). The mean age at presentation was 32.7±8.4 years (Females 57%). Six eyes were being treated with anti-VEGF therapy for CNV. Mean follow-up after baseline was 15.3±15.7 months. Mean LogMAR BCVA was 0.57±1.0 six months prior to baseline, and it remained stable at baseline and at 1,2, and 6 months after baseline (0.42±0.47 at six months;p=0.84). The mean dose of prednisone decreased significantly from 17.3±19.6 mg/day 6 months prior to the baseline to 4.7±3.95 mg/day at the last follow-up after baseline (p=0.03). There was a trend of a decrease in the number of anti-VEGF injections after baseline.
No ADA-related adverse events were noted.
|
| Conclusion | Adalimumab therapy of refractory PIC/MFC enabled a significant reduction in prednisone dose with stable BCVA and a good safety profile. |
| Conflict of interest | No |
Authors 1
| Last name | SHMUELI |
| Initials of first name(s) | O |
| Department | Department of Ophthalmology, Hadassah Medical Center |
| City | Jerusalem |
| Country | Israel |
Authors 2
| Last name | AMER |
| Initials of first name(s) | R |
| Department | Department of Ophthalmology, Hadassah Medical Center |
| City | Jerusalem |
| Country | Israel |
